Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Aetna (AET) to Acquire Humana (HUM) for $37 Billion, or $230/Share
- Top 10 News for 6/29 - 7/2: Greece's Bark Bites Markets; Tesla's Q2 Sales Outpace; Major Insurance Merger Announced
- Yelp (YELP) Sale Process Said to Stall as CEO Changes Mind
- UPDATE: Nonfarm Payrolls Added 223K in June, Missing Views Amid Gains in Health Care, Retail Trade
- Kraft Heinz Co (KHC) Announces Completion of Merger; Updates on Next Steps; Announces Dividend
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Biogen (BIIB), AGTC (AGTC) Enter Ophthalmic Disease Therapy Collaboration
- Roth Capital Positive on Biogen (BIIB), AGTC (ATGC) Collaboration; Reaffirms AGTC at 'Buy'
- Microsoft (MSFT) Offers Third Windows 10 Preview Build for the Week; Covers the 'Fast Ring'
Create E-mail Alert Related CategoriesFDA, Insiders' Blog
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!